Oppi

The industry body says it is collaborating, converging and co-creating with the government and other stakeholders to enable an innovative environment in India

'Freebies' to doctors: Pharma industry lobby seeks new code to regulate marketing interaction

The structure of interaction between pharma companies and doctors should be defined by the government, industry groups say. The Centre had earlier said the existing Universal Code of Pharmaceutical Marketing Practices worked adequately.

Exclusive I Indians spend Rs 35,820 crore a year on minor ailments, finds novel survey by pharma body

Citing the findings of the study, the Organisation of Pharmaceutical Producers of India has argued that coming up with a robust policy on over-the-counter drugs will empower people and pharmacists but experts slam the idea saying it can be counterproductive for a country like India.

Set up special high court benches with experts to resolve patent disputes, says OPPI chief Sridhar

Organisation of Pharmaceutical Producers of India president S Sridhar thinks innovation is the way forward and India’s pharma industry should build upon the opportunity provided by COVID to widen healthcare, improve production capacity and fight other diseases and epidemics

Want certainty and predictability in price control mechanism for drugs: OPPI

The industry body said it aims to make sure that innovative drugs that are available in the rest of the world are made available in India as soon possible.

Customs duty on drugs irrational; patients will suffer: Biocon

Kiran Mazumdar Shaw, CMD, Biocon, calls this to be an irrational commentary from the government‘s side, as it will only the end-user—the patient—who will have to pay the increased cost.

Pharma cos demand raise in public spending on healthcare

As public spending on healthcare in India is among the lowest in the world, the increased public spending and sustainable financing mechanisms may improve access to healthcare in the country, Organisation of Pharmaceutical Producers of India (OPPI) said in a paper titled 'Healthcare Financing'.

Tax battles have given India a bad name: Sanofi

Viebacher's views on regulatory hurdles in India were evidence of the long drawn tax liability battle it has waged against the Indian IT department over the acquisition of Indian vaccine maker Shantha Biotech.

Pharma body challenges government‘s method of pricing

The government wants more time to table its new drug pricing norms. The Supreme Court has deferred hearing the matter till the 12th of December. Meanwhile, the pharma pricing policy has been challenged by the All India Drug Action Network (AIDAN).

Analysts see no big impact of pricing policy on pharma cos

A new pricing policy finalised by a ministers panel on Thursday, which will bring 348 essential drugs under government price control, is unlikely to have a major impact on the earnings of pharmaceutical companies, according to analysts.

Budget Expectations: Pharma Producers body calls for infra status to healthcare

As 16 March draws close, Indian healthcare is once again at the crossroads waiting with bated breath for the Union Budget in the hope that it will provide the necessary impetus to the pharmaceutical industry. Announcing Infrastructure status for Healthcare would be just what the doctor ordered.

FDI cap in pharma to hurt global investor confidence: Body

Imposing restrictions on foreign direct investment (FDI) in the pharmaceutical space would hurt overseas investment flows into India and will send a wrong signal to global investors, reports the Economic Times quoting president of the Organisation of Pharmaceutical Producers of India (OPPI) Ranjit Shahani.